334 related articles for article (PubMed ID: 17072120)
21. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.
Richmond P; Borrow R; Goldblatt D; Findlow J; Martin S; Morris R; Cartwright K; Miller E
J Infect Dis; 2001 Jan; 183(1):160-3. PubMed ID: 11078484
[TBL] [Abstract][Full Text] [Related]
22. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
[TBL] [Abstract][Full Text] [Related]
23. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
[TBL] [Abstract][Full Text] [Related]
24. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.
Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
Clin Vaccine Immunol; 2012 Oct; 19(10):1561-6. PubMed ID: 22855388
[TBL] [Abstract][Full Text] [Related]
26. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.
Richmond P; Borrow R; Miller E; Clark S; Sadler F; Fox A; Begg N; Morris R; Cartwright K
J Infect Dis; 1999 Jun; 179(6):1569-72. PubMed ID: 10228085
[TBL] [Abstract][Full Text] [Related]
27. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life.
Diez-Domingo J; Planelles-Cantarino MV; Baldo-Torrenti JM; Ubeda-Sansano I; Jubert-Rosich A; Puig-Barbera J; Gutierrez-Gimeno MV
Pediatr Infect Dis J; 2010 Aug; 29(8):768-70. PubMed ID: 20375851
[TBL] [Abstract][Full Text] [Related]
28. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.
Keyserling HL; Pollard AJ; DeTora LM; Gilmet GP
Expert Rev Vaccines; 2006 Aug; 5(4):445-59. PubMed ID: 16989625
[TBL] [Abstract][Full Text] [Related]
29. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, and modified blind-observer study.
Al-Mazrou Y; Khalil M; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
Clin Vaccine Immunol; 2012 Jul; 19(7):999-1004. PubMed ID: 22552602
[TBL] [Abstract][Full Text] [Related]
31. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger.
Chippaux JP; Garba A; Ethevenaux C; Campagne G; de Chabalier F; Djibo S; Nicolas P; Ali H; Charrondière M; Ryall R; Bybel M; Schuchat A
Vaccine; 2004 Sep; 22(25-26):3303-11. PubMed ID: 15308353
[TBL] [Abstract][Full Text] [Related]
33. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine.
Clarke P; Robinson MJ; Ahmad I; Bedford-Russell AR; Connell JE; Powell PJ; Heath PT
Vaccine; 2006 Apr; 24(16):3273-8. PubMed ID: 16472548
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
[TBL] [Abstract][Full Text] [Related]
35. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.
Richmond P; Kaczmarski E; Borrow R; Findlow J; Clark S; McCann R; Hill J; Barker M; Miller E
J Infect Dis; 2000 Feb; 181(2):761-4. PubMed ID: 10669372
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.
Jackson LA; Jacobson RM; Reisinger KS; Anemona A; Danzig LE; Dull PM
Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603
[TBL] [Abstract][Full Text] [Related]
37. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine.
Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Oster P; Borrow R
Vaccine; 2014 Sep; 32(43):5715-21. PubMed ID: 25151042
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
[TBL] [Abstract][Full Text] [Related]
39. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
[TBL] [Abstract][Full Text] [Related]
40. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?
Tsai TF; Borrow R; Gnehm HE; Vaudaux B; Heininger U; Desgrandchamps D; Aebi C; Balmer P; Pedersen RD; Fritzell B; Siegrist CA
Clin Vaccine Immunol; 2006 Aug; 13(8):854-61. PubMed ID: 16893984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
